. Author manuscript; available in PMC: 2023 Sep 1.

Published in final edited form as: J Neuroophthalmol. 2022 Mar 25;42(3):323–327. doi: 10.1097/WNO.0000000000001536

Table 3.

Sensitivity Analysis. Using our estimate of at-risk patients for the state of Utah, we performed a sensitivity analysis to correct our overestimate of the incidence of tetracycline-induced pseudotumor cerebri syndrome (PTC-T).

	Prescribed Tetracycline
	Yes	No
PTCS (8 years)	45	274 – 45 = 229
At-Risk Population (8 years)	8,809	8,041,278 – 8,809 = 8,032,469
8-Year Incidence	45 / 8,809 = 0.00510841	229 / 8,032,469 = 0.00002851
Incidence Rate, per 100,000 person years	(45 / 8,809) ×100,000 = 510.8 per 100,000 person yrs*	(229 / 8,032,469) ×100,000 = 2.8 per 100,000 person yrs
Incidence Rate Ratio = 179 (130, 246), p < .001

FURTHeR = Federated Utah Research and Translational Health e-Repository; PTCS = pseudotumor cerebri syndrome. The incidence rate per 100,000 person-years is also an estimate of the one-year incidence.